The role of the intestinal microbiota in type 1 diabetes

Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA.
Clinical Immunology (Impact Factor: 3.67). 12/2012; 146(2):112-119. DOI: 10.1016/j.clim.2012.12.001
Source: PubMed


The digestive tract hosts trillions of bacteria that interact with the immune system and can influence the balance between pro-inflammatory and regulatory immune responses. Recent studies suggest that alterations in the composition of the intestinal microbiota may be linked with the development of type 1 diabetes (T1D). Data from the biobreeding diabetes prone (BBDP) and the LEW1.WR1 models of T1D support the hypothesis that intestinal bacteria may be involved in early disease mechanisms. The data indicate that cross-talk between the gut microbiota and the innate immune system may be involved in islet destruction. Whether a causal link between intestinal microbiota and T1D exists, the identity of the bacteria and the mechanism whereby they promote the disease remain to be examined. A better understanding of the interplay between microbes and innate immune pathways in early disease stages holds promise for the design of immune interventions and disease prevention in genetically susceptible individuals.

Download full-text


Available from: Diana Ir,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of review: Discuss recent data linking the intestinal microbiome with mechanisms of inflammation and islet destruction. Recent findings: Type 1 diabetes (T1D) is a proinflammatory disease that results in the loss of insulin-producing beta cells. How T1D is triggered is unclear; however, both genetic and environmental factors were implicated in disease mechanisms. Emerging evidence supports the notion that there is a complex interaction between the intestinal microbiome and the immune system and this cross-talk is involved in maintaining normal immune homeostasis in the gut and periphery. Under some circumstances the gut microbiota could lead to pathogenic immune responses resulting in inflammation in the intestine as well as other organs. Indeed, recent data from genetically susceptible individuals suggested that alterations in gut bacterial communities may be involved in the mechanism of islet destruction. Studies performed in animal models of T1D indicated that manipulating the gut microbiome can protect from islet destruction via mechanisms that may involve down-regulating both the adaptive and innate immune systems. Summary: Further work is required to identify specific bacterial communities and mechanisms involved in triggering T1D. A better knowledge of the role of the gut microbiome in islet destruction could lead to new clinical interventions to restore healthy homeostasis and prevent disease development.
    Current opinion in endocrinology, diabetes, and obesity 06/2013; 20(4). DOI:10.1097/MED.0b013e3283628569 · 3.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Type 1 diabetes (T1D) is an autoimmune form of diabetes mellitus that accounts for about 10% of all diabetes cases and occurs predominantly during childhood or adolescence. The disease initiates when most of the insulinproducing β-cells in the pancreas are destroyed by autoimmune cells, including T-helper1 cells, cytotoxic lymphocytes and dendritic cells. The major autoantigens in T1D are insulin, glutamic acid decarboxylase, and insulinoma antigen. At-risk individuals with underlying islet inflammation can be identified by the presence of circulating autoantibodies to these specific islet antigens many years before the clinical onset of T1D, thus, providing a window for prevention strategies. Currently, there is no definitive cure for T1D; therefore, more effective therapeutic interventions for prevention of diabetes onset and progression are urgently needed. Vaccination with autoantigens to promote selfantigen-specific tolerance represents the most specific and safest means of preventing autoimmune diseases.Autoantigens administered by the mucosal route, which is “tolerogenic” by nature, is the most effective way to prevent or treat autoimmune diseases. However, the two major drawbacks of oral vaccination with autoantigens arethe large quantities required to induce significant tolerance, presumably because the protein is partially degraded in the stomach, and the high cost of producing recombinant autoantigens using the conventional cell culture-based platforms. The expression of autoantigens in plants and the oral delivery of the plant tissue expressing the target antigen offer a potential solution for these two drawbacks. The goal of this review is to outline novel diabetes vaccinestrategies based on β-cell autoantigens with a focus on the advantages and potential of plant-produced islets self antigens and anti-inflammatory cytokines for the prevention and treatment of T1D
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating levels of adiponectin (APN) are reduced in obesity and associated comorbidities, with inflammation playing an important role in downregulating APN production. In contrast to obesity and metabolic disease, elevated systemic and local levels of APN are present in patients with inflammatory and immune-mediated diseases, including autoimmune and pulmonary conditions, heart and kidney failure, viral hepatitis, organ transplantation and perhaps critical illness. A positive association between inflammation and APN is usually reported in inflammatory/immune pathologies, in contrast with the negative correlation typical of metabolic disease. This review discusses the role of APN in modulation of inflammation and immunity and the potential mechanisms leading to increased levels of APN in inflammatory/immune diseases, including modification of adipose tissue physiology; relative contribution of different tissues and adipose depots; hormonal, pharmacological, nutritional and life style factors; the potential contribution of the microbiota as well as the role of altered APN clearance and release from T-cadherin-associated tissue reservoirs. Potential reasons for some of the apparently contradictory findings on the role of APN as a modulator of immunity and inflammation are also discussed, including a comparison of types of recombinant APN used for in vitro studies and strain-dependent differences in the phenotype of APN KO mice.
    Cytokine 07/2013; 64(1). DOI:10.1016/j.cyto.2013.06.317 · 2.66 Impact Factor
Show more